Drugs · acquisition-cost intelligence
Eprontia
Topiramate· ingredient topiramate· TOPIRAMATE 25 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$1.61
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other topiramate products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| topiramate | $0.04260 | −$1.56 |
| Topamax | $0.05949 | −$1.55 |
| TOPIRAMATE | $0.30433 | −$1.30 |
| Qsymia | $3.21 | +$1.60 |
| topiramate | $5.66 | +$4.06 |
| Trokendi XR | $9.01 | +$7.40 |
| Topiramate | $22.71 | +$21.10 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 4
Prior auth 49% · Step therapy 15% · Quantity limit 38% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.